Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ EVOK opened at $4.14 on Friday. The stock has a 50-day simple moving average of $5.07 and a two-hundred day simple moving average of $5.37. The firm has a market capitalization of $6.15 million, a P/E ratio of -0.38 and a beta of 0.16. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $15.84.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.